Teri L. Lawver's most recent trade in Altimmune Inc was a trade of 48,800 Stock Options (option to buy) done . Disclosure was reported to the exchange on Sept. 25, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Altimmune Inc | Teri L. Lawver | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Sep 2025 | 48,800 | 48,800 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Teri L. Lawver | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 69,800 | 69,800 | - | - | Stock Options (option to buy) | |
| DexCom | Teri L Lawver | EVP Chief Commercial Officer | 12 Mar 2024 | 4,764 | 66,641 (0%) | 0% | 134.4 | 640,333 | Common Stock | |
| DexCom | Teri L Lawver | EVP Chief Commercial Officer | 08 Mar 2024 | 26,053 | 71,405 (0%) | 0% | 0 | Common Stock | ||
| DexCom | Teri L Lawver | EVP Chief Commercial Officer | 08 Mar 2023 | 45,352 | 45,352 (0%) | 0% | 0.0 | 45 | Common Stock |